Individuals with Duchenne muscular dystrophy (DMD) have increased risk of obesity from prolonged glucocorticoid use and progressive muscle weakness. Over 50% have obesity by the teenage years.
Objectives:
The current study examines literature on obesity management in DMD and describes how obesity pharmacotherapy can be used in this high-risk cohort.
Methods:
This review was conducted in adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist. A Pubmed Database search was conducted from January 2000 to May 2024. Included terms were DMD and topiramate, phentermine, metformin, glucagon-like peptide-1 receptor agonist, semaglutide, and liraglutide. Eligible studies were cataloged to examine obesity pharmacotherapy, side effect profiles, and clinical outcomes.
Results:
Twenty studies met inclusion criteria, 18 on metformin. Reviewed studies varied in duration from 4 to 24 weeks, ages 6.5–44 years old, with 112 participants total (range: 1–30 participants). Included studies were: eight animal studies, six clinical trials, four reviews, one cohort study, and one case report. Primary outcomes varied among studies: muscular degeneration and function (15 articles), cardiac function (2 articles), weight loss (2 articles), and general endocrine care (1 article).
Conclusions:
Adjunct obesity pharmacotherapy use in youth with DMD is promising but needs to be confirmed. Large gaps include appropriate agent selection, side effect monitoring, and dose escalation. The overall quality of pediatric-specific evidence for the use of obesity pharmacotherapy in youth with DMD is low. Future research is needed to investigate how to safely utilize these agents.
Get full access to this article
View all access options for this article.
References
1.
BillichN, AdamsJ, CarrollK, et al.The relationship between obesity and clinical outcomes in young people with duchenne muscular dystrophy. Nutrients, 2022; 14(16).
SatreV, MonnierN, DevillardF, et al.Prenatal diagnosis of DMD in a female foetus affected by Turner syndrome. Prenat Diagn, 2004; 24(11):913–917.
7.
TakeshitaE, MinamiN, MinamiK, et al.Duchenne muscular dystrophy in a female with compound heterozygous contiguous exon deletions. Neuromuscul Disord, 2017; 27(6):569–573.
8.
WeberDR, HadjiyannakisS, McMillanHJ, et al.Obesity and endocrine management of the patient with Duchenne muscular dystrophy. Pediatrics, 2018; 142(Suppl 2):S43–S52.
9.
MartigneL, SalleronJ, MayerM, et al.Natural evolution of weight status in Duchenne muscular dystrophy: A retrospective audit. Br J Nutr, 2011; 105(10):1486–1491.
10.
WalkerM, McAdamL, AminR, et al.‘Our time is precious’: An exploration of parental feeding behaviours for boys with Duchenne muscular dystrophy. Child Care Health Dev, 2023; 49(2):366–372.
11.
SaureC, CaminitiC, WeglinskiJ, et al.Energy expenditure, body composition, and prevalence of metabolic disorders in patients with Duchenne muscular dystrophy. Diabetes Metab Syndr, 2018; 12(2):81–85.
12.
HankardR, GottrandF, TurckD, et al.Resting energy expenditure and energy substrate utilization in children with Duchenne muscular dystrophy. Pediatr Res, 1996; 40(1):29–33.
13.
HensonSE, LangSM, KhouryPR, et al.The effect of adiposity on cardiovascular function and myocardial fibrosis in patients with Duchenne muscular dystrophy. J Am Heart Assoc, 2021; 10(19):e021037.
14.
HuberFA, Del GrandeF, RizzoS, et al.MRI in the assessment of adipose tissues and muscle composition: How to use it. Quant Imaging Med Surg, 2020; 10(8):1636–1649.
15.
SherlockSP, PalmerJ, WagnerKR, et al.Dual-energy X-ray absorptiometry measures of lean body mass as a biomarker for progression in boys with Duchenne muscular dystrophy. Sci Rep, 2022; 12(1):18762.
16.
Rodríguez-CruzM, SanchezR, EscobarRE, et al.Evidence of insulin resistance and other metabolic alterations in boys with Duchenne or Becker muscular dystrophy. Int J Endocrinol, 2015; 2015:867273.
17.
JeronimoG, NozoeKT, PoleselDN, et al.Impact of corticotherapy, nutrition, and sleep disorder on quality of life of patients with Duchenne muscular dystrophy. Nutrition, 2016; 32(3):391–393.
18.
McPhersonAC, AminR, McAdamL, et al.Growth assessment and weight management in paediatric neuromuscular clinics: A cross-sectional survey across Canada. Disabil Rehabil, 2021; 43(21):3015–3020.
19.
SawnaniH, ThampratankulL, SzczesniakRD, et al.Sleep disordered breathing in young boys with Duchenne muscular dystrophy. J Pediatr, 2015; 166(3):640–645.e1.
20.
CrescimannoG, GrecoF, D’AliaR, et al.Quality of life in long term ventilated adult patients with Duchenne muscular dystrophy. Neuromuscul Disord, 2019; 29(8):569–575.
21.
WeiY, SpeechleyK, CampbellC. Health-related quality of life in children with Duchenne muscular dystrophy: A review. J Neuromuscul Dis, 2015; 2(3):313–324.
22.
FreytagJM, RyanTD, BangeJE, et al.Obesity and loss of ambulation are associated with lower extremity oedema in Duchenne muscular dystrophy. Cardiol Young, 2023; 33(4):597–602.
23.
WalkerM, MistryB, AminR, et al.A qualitative exploration of the priorities and experiences of children with Duchenne muscular dystrophy, their parents, and healthcare professionals around weight management. Disabil Rehabil, 2022; 44(26):8234–8242.
24.
HuangM, ChenT, WangY, et al.Chronic pain, psychological distress, and quality of life in males with Duchenne muscular dystrophy. Dev Med Child Neurol, 2023; 65(5):640–654.
25.
Bernabe-GarcíaM, Rodríguez-CruzM, AtilanoS, et al.Body composition and body mass index in Duchenne muscular dystrophy: Role of dietary intake. Muscle Nerve, 2019; 59(3):295–302.
26.
BillichN, EvansM, TrubyH, et al.The association between dietary factors and body weight and composition in boys with Duchenne muscular dystrophy. J Hum Nutr Diet, 2022; 35(5):804–815.
27.
SaleraS, MenniF, MoggioM, et al.Nutritional challenges in Duchenne muscular dystrophy. Nutrients, 2017; 9(6).
28.
BrumbaughD, WatneL, GottrandF, et al.Nutritional and gastrointestinal management of the patient with Duchenne muscular dystrophy. Pediatrics, 2018; 142(Suppl 2):S53–S61.
29.
BirnkrantDJ, BushbyK, BannCM, et al.DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol, 2018; 17(3):251–267.
30.
HamplSE, HassinkSG, SkinnerAC, et al.Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics, 2023; 151(2).
31.
HoM, GarnettSP, BaurL, et al.Effectiveness of lifestyle interventions in child obesity: Systematic review with meta-analysis. Pediatrics, 2012; 130(6):e1647–e1671.
32.
ConcepcionJQ, TuckerLY, HuangK. Metformin for pediatric obesity and insulin resistance: A retrospective study within an integrated health care system. Obesity (Silver Spring), 2021; 29(9):1526–1537.
33.
NaseriA, SanaieS, HamzehzadehS, et al.Metformin: New applications for an old drug. J Basic Clin Physiol Pharmacol, 2023; 34(2):151–160.
34.
BonatiU, HafnerP, ErneB, et al.Improved muscle function in Duchenne muscular dystrophy using a combination of L-Arginine and Metformin. Neuropediatrics, 2015; 46(S 01):PS02–P34.
35.
HafnerP, BonatiU, RubinoD, et al.Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: Study protocol for a single-centre, randomised, placebo-controlled trial. Trials, 2016; 17(1):389.
36.
DongX, HuiT, ChenJ, et al.Metformin increases sarcolemma integrity and ameliorates neuromuscular deficits in a murine model of Duchenne muscular dystrophy. Front Physiol, 2021; 12:642908.
TaySK, OngHT, LowPS. Transaminitis in Duchenne’s muscular dystrophy. Ann Acad Med Singap, 2000; 29(6):719–722.
39.
KutlukMG, DoğanÇS. Kidney involvement and associated risk factors in children with Duchenne muscular dystrophy. Pediatr Nephrol, 2020; 35(10):1953–1958.
40.
CasteelsK, FieuwsS, van HelvoirtM, et al.Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit. Pediatr Diabetes, 2010; 11(1):61–69.
41.
GuoZ, GengM, HuangY, et al.Upregulation of Wilms’ Tumor 1 in epicardial cells increases cardiac fibrosis in dystrophic mice. Cell Death Differ, 2022; 29(10):1928–1940.
42.
AngebaultC, PanelM, LacôteM, et al.Metformin reverses the enhanced myocardial sr/er-mitochondria interaction and impaired complex i-driven respiration in dystrophin-deficient mice. Front Cell Dev Biol, 2020; 8:609493.
43.
DhillonS. Phentermine/Topiramate: Pediatric first approval. Paediatr Drugs, 2022; 24(6):715–720.
44.
KramerCK, LeitãoCB, PintoLC, et al.Efficacy and safety of topiramate on weight loss: A meta-analysis of randomized controlled trials. Obes Rev, 2011; 12(5):e338–e347.
45.
CarterGT, YudkowskyMP, HanJJ, et al.Topiramate for weight reduction in Duchenne muscular dystrophy. Muscle Nerve, 2005; 31(6):788–789.
46.
KheraR, MuradMH, ChandarAK, et al.Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. JAMA, 2016; 315(22):2424–2434.
47.
ChaoAM, WaddenTA, BerkowitzRI. The safety of pharmacologic treatment for pediatric obesity. Expert Opin Drug Saf, 2018; 17(4):379–385.
48.
RubinoDM, GreenwayFL, KhalidU, et al.STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA, 2022; 327(2):138–150.
49.
DengY, ParkA, ZhuL, et al.Effect of emaglutide and liraglutide in individuals with obesity or overweight without diabetes: A systematic review. Ther Adv Chronic Dis, 2022; 13:20406223221108064.
50.
HongY, LeeJH, JeongKW, et al.Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy. J Cachexia Sarcopenia Muscle, 2019; 10(4):903–918.
51.
GaddeKM, AllisonDB, RyanDH, et al.Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. Lancet, 2011; 377(9774):1341–1352.
52.
GarveyWT, RyanDH, LookM, et al.Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr, 2012; 95(2):297–308.
53.
AllisonDB, GaddeKM, GarveyWT, et al.Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP). Obesity (Silver Spring), 2012; 20(2):330–342.
54.
WaddenTA, BaileyTS, BillingsLK, et al.STEP 3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA, 2021; 325(14):1403–1413.
55.
WeghuberD, BarrettT, Barrientos-PérezM, et al.STEP TEENS Investigators. Once-weekly semaglutide in adolescents with obesity. N Engl J Med, 2022; 387(24):2245–2257.
56.
RubinoD, AbrahamssonN, DaviesM, et al.STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 2021; 325(14):1414–1425.
